About Gliknik - Management
David S. Block - President and CEO
David founded Gliknik after 17 years in industry, twelve of which were in a series of commercial positions at DuPont Merck and DuPont Pharmaceuticals including sales management, licensing, portfolio planning, market development, and product launch. He was the Executive Vice President of International Operations at the time of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb. From 2002 to 2004 David was the Chief Operating Officer of Celera Genomics. Prior to founding Gliknik, he founded and for three years ran Ruxton Pharmaceuticals, Inc., a venture-backed CNS start-up.
Henrik S. Olsen Ph.D. - Director, Drug Discovery
Dr. Olsen was one of the first ten employees at Human Genome Sciences. A graduate of the University of Aarhaus, Denmark, he completed his post-doctoral fellowship at the Roche Institute of Molecular Biology. Henrik is a named inventor on 61 issued U.S. patents. He has day-to-day responsibility and oversight for drug design, production, and analysis at Gliknik.
Scott E. Strome, M.D. - Founding Scientist
Dr. Strome is Professor and Chairman of the Department of OTO-HNS at the University of Maryland School of Medicine. Dr. Strome has a secondary appointment as a Professor in the Department of Immunology and Microbiology and also serves as the Director of the Tumor Immunology Program at the Marlene and Stewart Greenebaum Cancer Center at the University of Maryland. Previously, he was an Associate Professor of OTO-HNS at the Mayo Clinic College of Medicine. Dr. Strome received his medical degree from the Harvard Medical School and completed his residency in OTO-HNS at the University of Michigan. He currently runs a large translational immunology laboratory dedicated to the development of active and passive immunologic approaches for the treatment of malignant disease. Dr. Strome has day-to-day oversight for biology at Gliknik